You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 19, 2026

MARCAINE HYDROCHLORIDE W Drug Patent Profile

✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Marcaine Hydrochloride W, and when can generic versions of Marcaine Hydrochloride W launch?

Marcaine Hydrochloride W is a drug marketed by Hospira and is included in one NDA.

The generic ingredient in MARCAINE HYDROCHLORIDE W is bupivacaine hydrochloride; epinephrine bitartrate. There are twelve drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the bupivacaine hydrochloride; epinephrine bitartrate profile page.

AI Deep Research

Questions you can ask:

What is the 5 year forecast for MARCAINE HYDROCHLORIDE W?
What are the global sales for MARCAINE HYDROCHLORIDE W?
What is Average Wholesale Price for MARCAINE HYDROCHLORIDE W?

Summary for MARCAINE HYDROCHLORIDE W

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for MARCAINE HYDROCHLORIDE W

+ Get email alerts for changes to this table

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hospira	MARCAINE HYDROCHLORIDE W/ EPINEPHRINE	bupivacaine hydrochloride; epinephrine bitartrate	INJECTABLE;INJECTION	016964-004	Approved Prior to Jan 1, 1982	AP	RX	Yes	Yes	⤷ Get Started Free	⤷ Get Started Free				⤷ Get Started Free
Hospira	MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE	bupivacaine hydrochloride; epinephrine bitartrate	INJECTABLE;INJECTION	016964-007	Approved Prior to Jan 1, 1982	AP	RX	Yes	Yes	⤷ Get Started Free	⤷ Get Started Free				⤷ Get Started Free
Hospira	MARCAINE HYDROCHLORIDE W/ EPINEPHRINE	bupivacaine hydrochloride; epinephrine bitartrate	INJECTABLE;INJECTION	016964-008	Approved Prior to Jan 1, 1982	AP	RX	Yes	Yes	⤷ Get Started Free	⤷ Get Started Free				⤷ Get Started Free
Hospira	MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE	bupivacaine hydrochloride; epinephrine bitartrate	INJECTABLE;INJECTION	016964-013	Approved Prior to Jan 1, 1982	AP	RX	Yes	Yes	⤷ Get Started Free	⤷ Get Started Free				⤷ Get Started Free
Hospira	MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE	bupivacaine hydrochloride; epinephrine bitartrate	INJECTABLE;INJECTION	016964-010	Approved Prior to Jan 1, 1982	AP	RX	Yes	Yes	⤷ Get Started Free	⤷ Get Started Free				⤷ Get Started Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.